• Mariam Salisu Orhurhu, Robert Chu, Lauren Claus, Jacob Roberts, Bisi Salisu, Ivan Urits, Ejovwoke Orhurhu, Omar Viswanath, Alan D Kaye, Aaron J Kaye, and Vwaire Orhurhu.
• Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
• Curr Pain Headache Rep. 2020 Jul 24; 24 (9): 52.

Purpose Of ReviewSickle cell disease (SCD) remains among the most common and severe monogenic disorders present in the world today. Although sickle cell pain has been traditionally characterized as nociceptive, a significant portion of sickle cell patients has reported neuropathic pain symptoms. Our review article will discuss clinical aspects of SCD-related neuropathic pain, epidemiology of neuropathic pain among individuals with SCD, pain mechanisms, and current and future potential pharmacological interventions.Recent FindingsNeuropathic pain in SCD is a complicated condition that often has a lifelong and significant negative impact on life; therefore, improved pain management is considered a significant and unmet need. Neuropathic pain mechanisms are heterogeneous, and the difficulty in determining their individual contribution to specific pain types may contribute to poor treatment outcomes in this population. Our review article outlines several pharmacological modalities which may be employed to treat neuropathic pain in SCD patients.

18 keywords...

hide…